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INTRODUCTION
Helicobacter pylori (H. pylori) 
eradication is recommended in 
patients with different gastro-
duodenal and extra-intestinal 
diseases [1, 2]. However, it 
remains challenging since no first-
line therapy achieves a 100% cure 
rate [3]. Conversely, the success 
rate following standard therapies 
is declining [4, 5], mainly due 
to the increased resistance 
towards both clarithromycin 
and metronidazole worldwide 
[6], a trend seen in Italy as well 
[7]. Similarly, the efficacy of 
levofloxacin-amoxicillin triple 
therapy, generally used as a 
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ABSTRACT
Background & Aims: Helicobacter pylori (H. pylori) eradication in patients who failed one or more therapeutic 
attempts remains challenging. This study aimed to assess the efficacy of three-in-one capsules bismuth-based 
quadruple therapy (Pylera®) in these patients managed in clinical practice.  
Methods: This was a prospective, open-label, multicenter study enrolling consecutive, adult patients with 
persistent H. pylori infection following at least one standard therapy. All patients received a rescue quadruple 
therapy with Pylera (3 capsules four times daily) and esomeprazole 20 mg (1 tablet twice daily) for 10 days. 
H. pylori eradication was assessed by using Urea Breath Test 4-6 weeks following therapy ending. H. pylori 
eradication rates, compliance, and side-effects were calculated.  
Results: A total of 208 patients in the 9 participating centres were enrolled. Overall, 180 patients were 
successfully cured from the infection, accounting for 86.5% (95% CI 81.9-91.2) and 92.3% (95% CI 88.6-96.1) 
eradication rates at intention-to-treat analysis and at per protocol analysis, respectively. Cure rates were similar 
across patients who failed one to three previous therapy attempts, but the success rate fell to 67% after 4 or 
more therapy failures. Compliance to therapy was good in 198 (95.2%) patients, whilst in 7 (5.3%) cases the 
therapy was interrupted within 5 days due to side effects. A total of 97 (46.6%) patients complained of at least 
one side effect; nausea, diarrhea and vomiting were the most frequently reported.  
Conclusions: Our study found that this bismuth-based quadruple therapy is highly effective as second-line 
and rescue therapy for H. pylori eradication in clinical practice. 
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second-line treatment [8], has decreased so that the therapeutic 
options for curing H. pylori infection in clinical practice 
are quite limited [9, 10]. The interest towards the bismuth-
based quadruple therapy has recently been renewed by the 
marketing of a novel, three-in-one capsule, containing bismuth, 
tetracycline, and metronidazole (Pylera®), firstly introduced in 
2001 [11]. The bismuth-based quadruple therapy is advised as 
first-line or rescue therapy by different guidelines, including 
the updated Italian guidelines [1, 12, 13]. A high efficacy of 
such therapy is expected in those geographic areas where a low 
prevalence of primary tetracycline in H. pylori isolates is low. 
Unfortunately, despite the three-in-one capsule formulation, 
as many as 3 tablets four times daily for 10 days plus 2 proton 
pump inhibitor tablets (equaling 14 tablets per day) must 
be taken. Therefore, patients’ compliance with this therapy 
could be a matter for concern in the real-life, especially in 
elderly patients or those already taking drugs for other chronic 
diseases. Therefore, we assessed the efficacy of bismuth-based 
quadruple regimen in patients who failed at least one standard 
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eradication therapy, consecutively observed in clinical practice 
in different centers.    
PATIENTS AND METHODS
Patients
This was a prospective, open-label study enrolling 
consecutive, adult patients with persistent H. pylori infection 
following at least one standard therapy, observed in clinical 
practice in out-patient Gastrointestinal Clinics. Patients with 
major liver or kidney diseases, those with known allergy to the 
prescribed drugs, and pregnant or breast feeding women were 
excluded from the study. Persistent infection was documented 
by either 13C-urea breath test (UBT) or upper endoscopy with 
histological assessment. The UBT was done after an overnight 
fast. A baseline breath sample was obtained, and a 100 mg 
of 13C-urea with citric acid (1.5 mg) was administered as an 
aqueous solution, and another breath sample was collected 
following 30 minutes. The results of the test were considered 
positive if the difference between the baseline sample and 
the 30-minute sample exceeded 4.5 parts per 1000 of 13CO2, 
according to the manufacturer’s instructions. For each 
consenting patient, the main clinical data and the previous 
therapeutic attempts were collected. The study was performed 
according to guidelines for Good Clinical Practice [12] and 
the Declaration of Helsinki (1996 version, amended October 
2000) [13]. 
Therapy regimen
A rescue quadruple therapy with the three-in-one capsules 
plus the proton pump inhibitor was prescribed, as suggested in 
the current European and Italian guidelines [14, 15],
In detail, esomeprazole 20 twice ½ hour before breakfast 
and dinner, and three Pylera capsules four times daily 
(following breakfast, lunch, dinner and at bedtime, after 
eating a snack) were administered for 10 days, according 
to the manufacturer’s suggestions. After the initial visit, 
patients were fully explained about the need for such 
regimen and strongly encouraged to comply fully, in order 
to minimize the rate of drop-outs. A self-explanatory page 
with the therapeutic scheme was given. The use of alcohol 
was discouraged during the therapy. The patients were 
instructed about the possibility that dark stools and the 
metallic taste could appear during therapy, and that such 
events were clinically irrelevant. The drugs for other diseases 
were continued without changing during the eradication 
therapy. At the end of antibiotic treatment, the patients were 
interviewed again to assess the compliance to the therapy and 
the incidence of side-effects. Compliance was considered 
good when ≥90% of prescribed drugs were taken, acceptable 
when between >50% and 89%, whilst those patients who 
consumed ≤50% of prescribed drugs were considered as 
drop-outs. Side-effects were scored on a semi-quantitative 
scale as mild (present, but easily tolerable), moderate 
(fastidious, but not requiring therapy interruption), and 
severe (intolerable, requiring the interruption of therapy). 
H. pylori eradication was assessed by using UBT, 4-6 weeks 
following therapy ending. At least 10 consecutive patients 
had to be enrolled in each participating centers. 
Statistical analysis 
The cure rates were calculated as a percentage with their 
95% confidence intervals, at both ‘intention-to-treat’ (ITT) 
and ‘per protocol’ (PP) analyses. The ITT included all patients 
who took at least one drug dose, but failed to complete therapy 
or when they did not complete follow-up for any reason. The 
PP analysis considered patients with good compliance to the 
therapy and underwent the scheduled UBT control. Before 
pooling the estimates, the chi-squared test or Fisher’s exact test 
were applied to investigate the heterogeneity among centers. The 
SPSS (version 16.0) was used for all statistical computations.
RESULTS
A total of 9 centres participated in this study, distributed 
throughout northern (2 centres), central (3 centres) and 
southern (4 centres) Italy. The main demographic and clinical 
characteristics of the 208 enrolled patients are listed in Table 
I. Overall, 13 patients were considered drop-outs due to 
either therapy compliance less than 5 days (5 cases) or  those 
who failed to undergo the scheduled UBT control (8 cases). 
Therefore, there were 208 and 195 patients included at ITT 
and PP analyses, respectively. A total of 180 patients were 
successfully cured from the infection, accounting for an 86.5% 
(95% CI 81.9-91.2) eradication rate at ITT analysis and a 
92.3% (95% CI 88.6-96.1) at PP analysis. The eradication rates 
according to the number of previous failed therapy attempts 
were provided in Table II. Cure rates were similar across one to 
three therapy attempts, but the success rate fell to 67% after 4 
or more therapy failures. In detail, eradication rates remained 
comparable across the second-line or rescue therapy (74/87, 
85.1% vs. 106/121, 87.6%; P = 0.6). Similarly, no difference 
Table I. Demographic and clinical characteristics of the patients.
Variable Number
Patients 208
Age (mean±SD); years 53.8 ± 13.2
Males:Females 86:122
Smoking habit; (Yes/No/Not available) 50/99/59
Disease 64/9
Non-ulcer dyspepsia 163
Peptic ulcer/erosions 45
No. of previous eradication therapies
1 87
2 88
3 24
≥ 4 9
No. of other concomitant therapies
None 73
1 39
2 18
3 7
4 5
5 5
Not available 59
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was noted when comparing the cure rates between males and 
females (87.2% vs. 86.1%; P = 0.8), smokers and no smokers 
(82% vs. 84.8%; P = 0.6), patients with peptic ulcer/erosions or 
non-ulcer dyspepsia (88.9% vs. 85.9%; P = 0.4), and patients 
assuming ≤1 or >2 co-therapies (84.8% vs. 81.1%; P = 0.6). 
Compliance to therapy was good in 198 (95.2%) patients, 
and acceptable in further 5 patients (8 days in 3 patients, and 6 
days in other 2), whilst in 5 cases the therapy was interrupted 
within 5 days. Among the 5 patients with acceptable 
compliance, 3 were cured, 1 failed eradication, and the last 
one was a drop-out.
By excluding dysgeusia and stool darkening, at least one 
side-effect was complained by 97 (46.6%) patients, and the 
most frequently observed are listed in Table III. Moreover, 
there were 2 cases of monilial vaginitis, 1 of oral candidiasis, 
1 case of cystitis and 1 patient who developed onychomycosis. 
Side-effects were mild in the majority of cases, but in 11 (5.3%) 
patients therapy was discontinued earlier due to vomiting in 
4 cases (Days: 6, 4, 4, and 3), nausea in 3 (Days: 9, 9, and 8), 
diarrhea in 2 (Days: 8, and 4), oral candidiasis (Days: 8), and 
urticaria (Days: 6).     
DISCUSSION
Curing H. pylori infection following first-line therapy 
failure is notoriously difficult [16]. Different guidelines advise 
the use of a levofloxacin-amoxicillin based triple therapy 
as second-line regimen [1, 14, 15]. However, the success 
rate following this therapy seems to be declining in several 
countries, including Italy, most likely due to an increased 
prevalence of levofloxacin-resistant H. pylori strains [17]. 
In previous Italian, multicenter studies, a 76.4% and 76% 
eradication rates were achieved when such a therapy regimen 
was administered as a second- or third-line treatment, 
respectively [16, 18]. Regrettably, no novel molecules active 
towards H. pylori strains have been introduced, so that 
clinicians are left with 5-6 antibiotics to use in combination. 
Moreover, some delivery problems emerged with bismuth salts 
and tetracycline in different countries, including Italy, so that 
the use of bismuth-based quadruple therapy has been largely 
limited in the last decade in several countries [19]. Starting 
March 2016, Pylera® has become available in Italy. Therefore, 
we assessed the efficacy of such a bismuth-based quadruple 
therapy for curing H. pylori in patients with persistent infection 
despite one or more therapeutic attempts. 
Overall, our data showed an eradication rate as high as 
86.5%, which is particularly impressive when considering that 
the enrolled patients already had failed different eradication 
therapies. Of note, we observed that the success rate of such 
a therapy did not significantly decrease when administered 
as a second-line until to the fourth-line regimen. Moreover, 
the efficacy is not affected by any of the considered factors, 
including sex, smoking habit, and gastroduodenal disease. 
However, the success rate decreased to 67% after 4 or more 
therapy failures. Our data are in agreement with results of 
other studies recently performed in Spain and Italy, showing an 
82.4% cure rate on 14 patients treated from second- to fourth-
line [20] and 55.6%-80.2% as third-line therapy [21, 22]. We 
also observed that patients’ compliance to therapy was good 
(≥90% of prescribed drugs) in 95.2% of patients, despite the 
large number of tablets needed daily. Likewise, such a good 
result depends on a high motivation of the enrolled patients, 
who already have experienced previous therapy failures. In this 
respect, the importance of a strong patient-doctor interaction 
should be stressed. Indeed, the majority of patients continued 
therapy despite the fact that nearly  half of the cases complained 
of one or more mild side-effects. Luckily, side-effects required 
an earlier therapy interruption in only 5.3% of patients. Our data 
are similar with the 47%-67.3% incidence of side-effects and 
3%-8.7% interruption rate observed in other studies [22-25]. 
Table II. Eradication rate at ITT analysis according to the previous failed 
therapies
No. of previous therapies Cured/Total Eradication rate %; 
(95% CI)
1 74/87 85.1 (77.6-92.5)
2 79/88 89.9% (83.4-96.1)
3 21/24 87.5% (74.3-100)
≥4 (from 4 to 7) 6/9 66.7% (35.8-97.4)
Table III. List of most frequent side-effects
Side-effects Number (%)
Nausea 35 (16.8)
Mild 26
Moderate 6
Severe 3
Diarrhoea 18 (8.6%)
Mild 16
Moderate -
Severe 2
Vomiting 10 (4.8%)
Mild 2
Moderate 4
Severe 4
Abdominal pain 8 (3.8)
Mild 8
Moderate -
Severe -
Urticaria/pruritus 6 (2.9)
Mild 4
Moderate 1
Severe 1
Headache 5 (2.4)
Mild 5
Moderate -
Severe -
Muscular cramps 4 (1.9)
Mild 4
Moderate -
Severe -
More than 1 symptom may be present in a single 
patient.
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Our results may also depend on a very low prevalence of 
primary tetracycline in H. pylori isolates in Italy [26], as in other 
European countries. Unfortunately, tetracycline resistance is 
already as high as 8.8% in Korea, 26.8% in Chile, and 43.9% 
in Cameroon [24].
Our study has some strengths. Patients were enrolled 
in different centers throughout Italy, so that the results are 
representative of different areas. The study involved a large 
number of patients (more than 200) who had  failed at least 
one eradication therapy.  Half of these patients received this 
quadruple therapy as second-, third-, and even fourth-line 
therapy. We performed the study in a clinical practice, where 
patients were receiving co-therapies (≥3 drugs in our series) 
potentially affecting compliance to this eradication therapy. 
Therefore, our data provide relevant information for the 
immediate application into the clinical practice in a setting of 
difficult to treat patients.
CONCLUSION
Our study found that this bismuth-based quadruple 
therapy is highly effective as second-line and rescue therapy 
for H. pylori eradication in clinical practice, most likely due 
to very low level of tetracycline resistance in Italy. Since the 
tetracycline resistance is expected to increase in different areas 
with the implementation of such a therapy, it could be wise to 
avoid its use as first-line therapy, at least in those areas where 
acceptable effective therapies are still available. 
Conflicts of interest: None to declare.
Author contributions: Z.A. conceived and designed the study. Z.A., 
D.F.V. and P.P. wrote the manuscript. All authors enrolled patients 
and approved the final version of the manuscript. 
REFERENCES
 1. Hunt RH, Xiao SD, Megraud F, et al; World Gastroenterology 
Organization. Helicobacter pylori in developing countries. World 
Gastroenterology Organization Global Guideline. J Gastrointestin Liver 
Dis 2011;20:299–304. 
 2. Alakkari A, Zullo A, O‘Connor HJ. Helicobacter pylori and 
nonmalignant diseases. Helicobacter 2011;16(Suppl 1):33–37. 
 3. De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori 
therapy: Present and future. World J Gastrointest Pharmacol Ther 
2012;3:68–73. doi:10.4292/wjgpt.v3.i4.68
 4. Di Ciaula A, Scaccianoce G, Venerito M, et al. Eradication rates 
in Italian subjects heterogeneously managed for Helicobacter 
pylori infection. Time to abandon empiric treatments in Southern 
Europe. J Gastrointestin Liver Dis 2017;26:129–137. doi:10.15403/
jgld.2014.1121.262.itl
 5. De Francesco V, Ridola L, Hassan C, et al. Two-week triple therapy 
with either standard or high-dose esomeprazole for first-line H. pylori 
eradication. J Gastrointestin Liver Dis 2016;25:147–150. doi:10.15403/
jgld.2014.1121.252.2w3
 6. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter 
pylori infection: systematic review and meta-analysis. Gastroenterology 
2017;153:420-429. doi:10.1053/j.gastro.2017.04.022
 7. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin 
resistance in Helicobacter pylori: the multicentric Italian clarithromycin 
resistance observational (MICRO) study. J Gastrointestin Liver Dis 
2011;20:235–239. 
 8. Zullo A, Ridola L, Efrati C, et al. First- and second-line Helicobacter 
pylori eradication with modified sequential therapy and modified 
levofloxacin-amoxicillin-based triple therapy. Ann Gastroenterol 
2014;27:357–361. 
 9. Fiorini G, Vakil N, Zullo A, et al. Culture-based selection therapy for 
patients who did not respond to previous treatment for Helicobacter 
pylori infection. Clin Gastroenterol Hepatol 2013;11:507–510. 
doi:10.1016/j.cgh.2012.12.007
 10. Ierardi E, Giangaspero A, Losurdo G, et al. Quadruple rescue therapy 
after first and second line failure for Helicobacter pylori treatment: 
comparison between two tetracycline-based regimens. J Gastrointestin 
Liver Dis 2014;23:367–770. doi:10.15403/jgld.2014.1121.234.qrth
 11. de Boer WA. A novel therapeutic approach for Helicobacter pylori 
infection: the bismuth-based triple therapy monocapsule. Expert Opin 
Investig Drugs 2001;10:1559–1566. doi:10.1517/13543784.10.8.1559
 12. International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH) adopts 
Consolidated Guideline on Good Clinical Practice in the Conduct of 
Clinical Trials on Medicinal Products for Human Use. Int Dig Health 
Legis 1997;48:231-234.
 13. WMA Declaration of Helsinki. Ethical Principles for Medical 
Research Involving Human Subjects. http://www.wma.net/
en/30publications/10policies/b3/ 
 14. Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter 
and Microbiota Study Group and Consensus panel. Management of 
Helicobacter pylori infection - the Maastricht V/Florence Consensus 
Report. Gut 2017;66:6–30. doi:10.1136/gutjnl-2016-312288
 15. Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management 
of Helicobacter pylori infection in Italy: The III Working Group 
Consensus Report 2015. Dig Liver Dis 2015;47:903–912. doi:10.1016/j.
dld.2015.06.010
 16. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan 
C. Second-line and rescue therapies for Helicobacter pylori eradication 
in clinical practice. J Gastrointestin Liver Dis 2010;19:131–134. 
 17. Saracino IM, Zullo A, Holton J, et al. High prevalence of primary 
antibiotic resistance in Helicobacter pylori isolates in Italy. J 
Gastrointestin Liver Dis 2012;21:363–365. 
 18. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple 
therapy in patients who have failed two eradication courses. Aliment 
Pharmacol Ther 2005;22:45–49. doi:10.1111/j.1365-2036.2005.02522.x
 19. Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: 
the comeback of bismuth-based quadruple therapy. Therap Adv 
Gastroenterol 2012;5:103–109. doi:10.1177/1756283X11432492
 20. Gómez Rodríguez BJ, Castro Laria L, Argüelles Arias, Castro Márquez C, 
Caunedo Álvarez Á, Romero Gómez M. A real life study of Helicobacter 
pylori eradication with bismuth quadruple therapy in naïve and 
previously treated patients. Rev Esp Enferm Dig 2017;109:552-558. 
doi:10.17235/reed.2017.4809/2016
 21. Di Ciaula A, Scaccianoce G, Venerito M, et al. Eradication rates 
in Italian subjects heterogeneously managed for Helicobacter 
pylori infection. Time to abandon empiric treatments in Southern 
Europe. J Gastrointestin Liver Dis 2017;26:129-137. doi:10.15403/
jgld.2014.1121.262.itl
 22. Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos 
Prieto HM, et al. Limited effectiveness with a 10-day bismuth-
Quadruple therapy for H. pylori 229
J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 225-229
containing quadruple therapy (Pylera®) in third-line recue treatment 
for Helicobacter pylori infection. A real-life multicenter study. 
Helicobacter 2017 Aug 3. [Epub ahead of print]. doi:10.1111/
hel.12423
 23. Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier 
JC. Rescue therapy with bismuth-containing quadruple therapy in 
patients infected with metronidazole-resistant Helicobacter pylori 
strains. Clin Res Hepatol Gastroenterol 2016;40:517–524. doi:10.1016/j.
clinre.2015.12.012
 24. Tursi A, Di Mario F, Franceschi M, et al. New bismuth-containing 
quadruple therapy in patients infected with Helicobacter pylori: a first 
Italian experience in clinical practice. Helicobacter 2017 Jan 26. [Epub 
ahead of print]. doi:10.1111/hel.12371 
 25. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication 
with a capsule containing bismuth subcitrate potassium, metronidazole, 
and tetracycline given with omeprazole versus clarithromycin-based triple 
therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 
2011;377:905-913. doi:10.1016/S0140-6736(11)60020-2
 26. Di Giulio M, Di Campli E, Di Bartolomeo S, et al. In vitro antimicrobial 
susceptibility of Helicobacter pylori to nine antibiotics currently 
used in Central Italy. Scand J Gastroenterol 2016;51:263-9. doi: 
10.3109/00365521.2015.1092577 
